Abstract. The glutathione S-transferase P1 (GSTP1) protein plays several critical roles in both normal and neoplastic cells, including phase II xenobiotic metabolism, stress responses, signaling and apoptosis. Overexpression of GSTP1 has been observed in many types of cancer, including head and neck squamous cell carcinoma (HNScc). However, the role of GSTP1 in HNScc is not well understood. We investigated the role of GSTP1 in two HNScc cell lines, HSc3 and SAS. Silencing of GSTP1 revealed that cancer cell proliferation was significantly decreased in both cell lines. In addition, the frequency of apoptotic cells increased following si-GSTP1 transfection of HSc3 and SAS cell lines. Growing evidence suggests that microRNAs (miRNAs) negatively regulate gene expression and can function as oncogenes or tumor suppressors in human cancer. Based on the results of web-based searches, miR-133a is a candidate miRNA targeting GSTP1. down-regulation of miR-133a has been reported in many types of human cancer, including HNScc. Transient transfection of miR-133a repressed the expression of GSTP1 at both the mRNA and protein levels. The signal from a luciferase reporter was significantly decreased at one miR-133a target site at the 3'UTR of GSTP1, suggesting that miR-133a directly regulates GSTP1. Our data indicate that GSTP1 may have an oncogenic function and may be regulated by miR-133a, a tumor suppressive miRNA in HNSCC. The identification of a novel oncogenic pathway could provide new insights into potential mechanisms of HNScc carcinogenesis.
Introduction
Head and neck squamous cell carcinoma (HNScc) constitutes the sixth most common malignancy worldwide (1) . In spite of considerable advances in surgery, radiotherapy and chemotherapy, the overall five-year survival rate for patients with this type of cancer is among the lowest of all major cancer types and has not improved dramatically during the last decade (2). Local tumor recurrence and distant metastasis after conventional therapy appear to be major contributing factors decreasing survival of HNScc patients. Therefore, understanding the molecular oncogenic pathways underlying HNScc would be helpful to improve diagnosis, therapy, and prevention of the disease.
Glutathione S-transferase P1 (GSTP1), a member of the GST enzyme superfamily, catalyzes the conjugation of electrophiles to glutathione in the process of detoxification (3) . Recently, we demonstrated that GSTP1 is highly expressed in human HNScc tissue (4) and is frequently overexpressed in many other cancers, including tumors of the brain, breast, ovary, esophagus, stomach, pancreas, colon, skin, kidney, lung, bile ducts, bladder and lymphatic and hematopoietic systems (5-10). As such, there has been considerable clinical interest in GSTP1 as a tumor marker and as a therapeutic target (11, 12) . However, little is known about the functional role of GSTP1 in HNScc.
microRNAs (miRNAs), are endogenous small non-coding RNAs (19-22 nucleotides) that can control gene expression by targeting mRNAs for cleavage or translational repression (13) . Bioinformatic predictions indicate that miRNAs regulate more than 30% of the protein coding genes (14) . It is estimated that approximately 1,000 miRNAs exist in the vertebrate genome. Release 16.0 of the miRBase database (http://microrna.sanger. ac.uk/) included 1,048 registered human miRNAs. Growing evidence suggests that miRNAs are involved in several crucial biological processes, including development, differentiation, apoptosis, and proliferation (13, 15 A search of the TargetScanHuman release 5.1 database, identified miR-133a as a candidate miRNA regulator of GSTP1. down-regulation of miR-133a has been reported in many types of human cancer, including HNScc (19) (20) (21) (22) . More recently, we demonstrated that miR-133a functions as a tumor suppressor in esophageal cancer and bladder cancer (23, 24) . In this study, we conducted a functional analysis of GSTP1 and investigated whether GSTP1 is directly regulated by miR-133a in HNScc cell lines. The identification of a novel oncogenic pathway could provide new insights into potential mechanisms of HNScc carcinogenesis. RNA isolation. Total RNA was isolated using TRIzol reagent (Invitrogen, carlsbad, cA) according to the manufacturer's protocol. RNA concentrations were determined spectrophotometrically, and the molecule integrity was checked by gel electrophoresis. RNA quality was confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa clara, cA).
Materials and methods

Clinical
Real-time quantitative RT-PCR. First-strand cdNA was synthesized from 1 µg total RNA using random primers and the Reverse Transcription (RT) system (Promega, Tokyo, Japan). Gene-specific PCR products were continuously assayed using a 7900-HT real-time PcR System according to the manufacturer's protocol (Applied Biosystems, Foster city, cA, USA). The initial PCR step consisted of a 10 min hold at 95˚C, followed by 40 cycles consisting of a 15 sec denaturation at 95˚C and a 1 min annealing/extension at 63˚C. TaqMan ® probes and primers for GSTP1 (P/N: Hs00168310_m1) and the GAPDH (A/N: NM_002046) internal control were obtained from Applied Biosystems (Assay-On-demand gene expression products). The expression levels of miR-133a (P/N: 002246) were analyzed by TaqMan quantitative real-time PcR (TaqMan ® MicroRNA Assay; Applied Biosystems) and normalized to RNU48 (A/N: X96648). All reactions were performed in triplicate, and included negative control reactions that lacked cdNA.
Immunoblotting and immunohistochemistry. cells were harvested 72 h after transfection and lysates were prepared. Fifty µg of protein from cell lysates were separated by NuPAGE on 4-12% Bis-Tris gels (Invitrogen) and transferred to PVdF membranes. Immunoblotting was performed with diluted (1:100) monoclonal GSTP1 antibody (ab47709, Abcam, cambridge, Uk). The β-actin antibody (sc-1615; Santa cruz Biotechnology, Santa cruz, cA, USA) was used as an internal control. The membrane was washed and incubated with goat anti-mouse IgG (H+L)-HRP conjugate (Bio-Rad, Hercules, cA, USA). Specific complexes were visualized by echochemiluminescence (GE Healthcare Bio-Sciences, Princeton, NJ, USA).
For immunohistochemistry, primary mouse monoclonal antibodies against GSTP1 (cell Signaling) were diluted 1:200. The slides were treated with biotinylated anti-mouse IgG (H+L) made in house (Vector Laboratories, Burlingame, cA, USA). diaminobenzidine-hydrogen peroxide (Sigma-Aldrich, St. Louis, MO, USA) was the chromogen, and counterstaining was carried out with 0.5% hematoxylin.
si-GSTP1 and mature miRNA transfection in HNSCC cell lines. As described previously (24, 25) , si-GSTP1 and si-control molecules were transfected into the HNScc cell lines with Opti-MEM (Invitrogen) and Lipofectamine™ RNAiMax reagent (Invitrogen). After co-transfecting 10 nM small interfering RNA, si-GSTP1 (P/N: s194476; Applied Biosystems) or si-control (D-001810-10; Thermo Fisher Scientific), HNSCC cells were seeded into 96-well plates at 3x10 3 cells per well for proliferation assays or 6-well plates at 3x10 4 for apoptosis assays.
Mature miRNA molecules, Pre-miR™ miRNA precursors, and a negative control (Applied Biosystems, Foster city, cA, USA) were incubated with Opti-MEM (Invitrogen) and Lipofectamine™ RNAiMax reagent (Invitrogen) as previously described (24, 25) . We first confirmed the transfection efficiency of Pre-miR™ in cell lines, based on the down-regulation of PTK9 mRNA by transfection with miR-1 (as recommended by the manufacturer).
Cell proliferation assay. cells were transfected with 10 nM siRNA or miRNA by reverse transfection and plated in 96-well plates at 3x10 3 cells per well. After 72 or 96 h, cell proliferation was determined by the XTT assay, using the cell Proliferation kit II (Roche Molecular Biochemicals, Mannheim, Germany) as previously described (24, 25) . Triplicate wells were measured for cell viability in each treatment group. Plasmid construction and the dual-luciferase reporter assay. miRNA target sequences were inserted between the XhoIPmeI restriction sites in the 3'UTR of the hRluc gene in the psicHEck™-2 vector (c8021; Promega, Madison, WI, USA). Primer sequences for the full-length 3'UTR of GSTP1 mRNA (TAGGcGATcGcTcGAGGGGTTGGGGGGAcTcTGA and TcTAGGTTTAAAcTTTATTGGTccTGGAGAAAGGA) were designed. SAS cells were transfected with 5 ng of vector, 10 nM miRNAs, and 1 µl of Lipofectamine™ 2000 (Invitrogen) in 100 µl of Opti-MEM™ (Invitrogen). The activities of firefly and Renilla luciferases in cell lysates were determined with a dual-luciferase assay system (E1910; Promega). Normalized data were calculated as the quotient of Renilla/firefly luciferase activities.
Results
Effect of GSTP1 silencing on cell proliferation in HNSCC cell lines.
To examine the effect of silencing of GSTP1, si-GSTP1 was transfected into HSC3 and SAS cell lines. The efficiency of both mRNA and protein silencing of GSTP1 were evaluated in the siRNA transfectant cell lines. The expression levels of both mRNA and protein were clearly reduced in the si-GSTP1 transfectant cells (Fig. 1) .
We monitored cellular proliferation after si-GSTP1 transfection in HSc3 and SAS cell lines. The XTT assay revealed that cell viability significantly decreased in a time-dependent manner in the si-GSTP1 transfectants in comparison with the si-control in both HSc3 and SAS cells (Fig. 2) . In HSc3 cells, the cell growth of si-GSTP1 transfectants was 65.3% and 50.5% (both P<0.05) of that seen in si-controls after 72 h and 96 h, respectively. Similarly, in SAS cells, cell growth after 72 h and 96 h was 42.7%, and 35.2% of control, respectively (both P<0.05).
The effect of GSTP1 silencing on apoptosis was analyzed using flow cytometry. In HSC3 cells, GSTP1 silencing resulted in a 4.85-fold increase in the proportion of early apoptotic cells (Fig. 3, upper panels) while in SAS cells, it resulted in a 7.23-fold increase in the total proportion of early apoptotic cells after si-GSTP1 transfection (Fig. 3, lower panels) .
GSTP1 as a target of post-transcriptional repression by miR-133a.
Interestingly, GSTP1 3'UTR contains a predicted target sequence for miR-133a suggesting it might function as a tumor suppressive miRNA. The expression levels of GSTP1 mRNA and GSTP1 protein were markedly reduced in miR-133a transfectant cells when compared to miRNA-control transfectants (Fig. 4) . This suggests that miR-133a regulates GSTP1 expression by cleavage or translational inhibition. We performed a luciferase reporter assay to determine whether GSTP1 mRNA is an actual target site for miR-133a, as indicated by the TargetScan program (release 5.1, http://www.targetscan. org/). We constructed a vector encoding the full-length 3'UTR of GSTP1 mRNA and found that the luminescence intensity 
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was significantly lower (P<0.05) in the miR-133a transfectant (Fig. 5) .
Underexpression of miR-133a and overexpression of GSTP1 protein in HNSCC clinical specimens.
The expression levels of miR-133a were evaluated using 20 HNScc clinical specimens. Levels of miR-133a were significantly lower (P=0.005) in cancerous tissues than in non-cancerous tissues (Fig. 6A) . In contrast, the expression levels of GSTP1 protein were up-regulated in cancer cells as determined by immunohistochemistry (Fig. 6B) . Representative data of twenty HNScc patients are described in Table I . 
Discussion
GSTs are phase II detoxification enzymes that catalyze the conjugation of electrophilic compounds with reduced glutathione (3). Among the GSTs, GSTP1 is frequently overexpressed in many cancers (5) (6) (7) (8) (9) (10) . Recently, we reported that mRNA levels of GSTP1 were highly expressed in HNScc tissues compared to adjacent non-cancerous tissues (4). Furthermore, GSTP1 has been mapped to human chromosome 11q13 and this region is frequently altered in human HNScc clinical specimens (26, 27) . Expression of GSTP1 mRNA has been correlated with chromosomal alterations in HNScc (4). However, the biological result of GSTP1 overexpression in HNScc remains unclear.
In this study, we explored silencing of GSTP1 in two HNScc cell lines, HSc3 and SAS. The analysis showed that GSTP1 plays an oncogenic role by inhibiting apoptosis. Enhanced GSTP1 expression might influence tumor growth by inhibition of apoptosis pathways, as reported in hepatic carcinoma, prostate cancer, small cell lung carcinoma, and myeloid leukemia (28) (29) (30) (31) . It has been shown that GSTP1 protein interacts with c-Jun NH 2 -terminal kinase (JNk) and tumor necrosis factor receptor-associated factor 2 (TRAF2), and suppresses the induction of apoptosis (32) . In HEk293 cells, overexpression of GSTP1 inhibited both MEkk1-and etoposide-induced apoptosis, and inhibited pro-caspase-3 activation and PARP cleavage (33) . In clinical specimens of bladder cancer, BcL2 protein expression and high GSTP1 expression were positively correlated (34) . These findings are consistent with our report. The molecular interplay between GSTP1 and the apoptotic cascade could provide new approaches for the development of cancer therapy.
Recently, it was reported that wild-type p53 regulates GSTP1 expression and protects the genome from alkylating and free radical-generating compounds (35) . Thus, it was of interest to determine which genes regulated GSTP1. We focused on miRNAs, an abundant class of small non-coding RNAs approximately 19-22 nucleotides in length that function as negative regulators of gene expression by antisense compli- GSTP1 mRNA expression was reduced in both miR-133a transfectants. The results were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPdH) expression. * P<0.05. (B) GSTP1 protein expression was analyzed by Western blot analysis 72 h after transfection of miR-133a. GSTP1 protein expression was also reduced in miR-133a transfectants. The membranes were blotted with anti-GSTP1 IgG and anti-β-actin was used as a loading control. The density of each protein band was quantified using NIH-ImageJ. The results were standardized against the levels of β-actin.
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mentarity to specific messenger RNAs (13) . A database search (TargetScan program: release 5.1, April 2009, http://www. targetscan.org/) revealed that miR-133a might target GSTP1 mRNA. Our study proved that GSTP1 expression was regulated through direct binding to a specific site in the 3'UTR. Several studies indicated that miR-133a controls cardiac hypertrophy, and it is significantly down-regulated in hypertrophic and failing hearts (36) . Targets of miR-133a are the Ras homolog gene family member A (RHOA) and the cell division cycle 42 (CDC42) genes (37, 38) . Expression of miR-133a is reduced in many cancers, including HNScc and oral cancer, suggesting its role as a tumor suppressive miRNA (19-21,24,39 ).
More recently, our studies demonstrated that miR-133a transfection of cancer cells significantly reduced cell proliferation, migration and invasion in bladder cancer, and esophageal squamous cell carcinoma. miR-133a directly regulated several oncogenic genes, such as FSCN1 and LASP1 (23, 24, 40) . Other groups also found that miR-133a inhibited proliferation and induced apoptosis in squamous cell carcinoma of the tongue, and directly controlled pyruvate kinase type M2 gene expression (39) . Thus, miR-133a regulates many oncogenic genes. How GSTP1 overexpression changes in many types of cancers is still unclear, but one possible mechanism is through regulation by miR-133a.
Together, our findings demonstrate that the tumor suppressor miR-133a, regulates GSTP1 expression and that overexpression of GSTP1 increases cell proliferation by inhibiting apoptotic pathways in HNScc. The therapeutic implications of these findings should be futher exploited towards the development of future HNScc treatments.
